Literature DB >> 9883974

Sensitivity to ageing of the limbic dopaminergic system: a review.

P Barili1, G De Carolis, D Zaccheo, F Amenta.   

Abstract

The limbic system includes the complex of brain centres, nuclei and connections that provide the anatomical substrate for emotions. Although the presence of small amounts of dopamine (DA) in several limbic structures has been recognized for a long time, for many years it was thought that limbic DA represented a precursor of noradrenaline in the biosynthetic pathway of catecholamines. More recent evidence has shown that limbic centres and nuclei are supplied with a dopaminergic innervation arising from the ventral tegmental area (field A10) and in smaller amounts from the mesencephalic A9 field. The dopaminergic limbic system is sensitive to ageing. Parameters of dopaminergic neurotransmission (DA levels, biosynthetic and catabolic markers and DA receptors) undergo age-related changes which depend on the structure and species investigated and are characterized mainly by a decline of different parameters examined. In this paper, the influence of ageing on DA biosynthesis, levels, metabolism and receptors are reviewed in laboratory rodents, monkeys and humans as well as in cases of Alzheimer's disease and Parkinson's disease. The possibility that changes of dopaminergic neurotransmission markers in the limbic system are associated with cognitive impairment and psychotic symptoms affecting the elderly is discussed. Better knowledge of dopaminergic neurotransmission mechanisms in the so-called physiological ageing and in senile dementia may provide new insights in the treatment of behavioural alterations frequently occurring in old age.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9883974     DOI: 10.1016/s0047-6374(98)00104-3

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  8 in total

1.  Neurotrophin receptor heterozygosity causes deficits in catecholaminergic innervation of amygdala and hippocampus in aged mice.

Authors:  O von Bohlen Und Halbach; L Minichiello
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

2.  Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.

Authors:  Venkatesh Pilla Reddy; Magdalena Kozielska; Martin Johnson; An Vermeulen; Rik de Greef; Jing Liu; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

3.  Pattern separation deficits may contribute to age-associated recognition impairments.

Authors:  Sara N Burke; Jenelle L Wallace; Saman Nematollahi; Ajay R Uprety; Carol A Barnes
Journal:  Behav Neurosci       Date:  2010-10       Impact factor: 1.912

4.  Involvement of BDNF in age-dependent alterations in the hippocampus.

Authors:  Oliver von Bohlen und Halbach
Journal:  Front Aging Neurosci       Date:  2010-08-13       Impact factor: 5.750

Review 5.  Advances in understanding the mechanisms and management of persistent pain in older adults.

Authors:  J F Karp; J W Shega; N E Morone; D K Weiner
Journal:  Br J Anaesth       Date:  2008-05-16       Impact factor: 9.166

6.  Huperzine A reverses cholinergic and monoaminergic dysfunction induced by bilateral nucleus basalis magnocellularis injection of beta-amyloid peptide (1-40) in rats.

Authors:  Yan Qi Liang; Xiao Tian Huang; Xi Can Tang
Journal:  Cell Mol Neurobiol       Date:  2007-07-17       Impact factor: 5.046

Review 7.  Brain plasticity-based therapeutics.

Authors:  Michael M Merzenich; Thomas M Van Vleet; Mor Nahum
Journal:  Front Hum Neurosci       Date:  2014-06-27       Impact factor: 3.169

Review 8.  Pharmacological pain management in the elderly patient.

Authors:  Gary McCleane
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.